Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study

Headache
Jerome GoldsteinRichard B Lipton

Abstract

Compare the effectiveness of a combination analgesic containing acetaminophen, aspirin, and caffeine to that of ibuprofen in the treatment of migraine. Multicenter, double-blind, randomized, parallel-group, placebo-controlled, single-dose study. A total of 1555 migraineurs were included in the analysis. No patients were excluded solely because of severity of symptoms or degree of disability. A single 2-tablet dose for each of the 3 treatment groups: a combination product containing acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg per tablet (AAC); ibuprofen 200 mg per tablet (IB); or matching placebo. The primary efficacy endpoint was the weighted sum of pain relief (PAR) scores at 2 hours postdose (TOTPAR2) and an important secondary endpoint was the time to onset of meaningful relief. There were 669 patients in the AAC group, 666 patients in the IB group, and 220 patients in the placebo group. The 3 treatment groups had similar demographic profiles, migraine histories, and baseline symptom profiles. While both active treatments were significantly better than placebo in relieving the pain and associated symptoms of migraine, AAC was superior to IB for TOTPAR2, as well as for PAR, time to onset of meaningful PAR, pain i...Continue Reading

References

Oct 1, 1994·Headache·R B LiptonS Solomon
Mar 1, 1997·Neurology·R B LiptonM von Korff
Oct 20, 1999·Cephalalgia : an International Journal of Headache·C Dahlöf
Sep 5, 2001·Cephalalgia : an International Journal of Headache·C Dahlöf, M Linde
Jun 30, 2004·Journal of Pain and Symptom Management·Thomas J SchnitzerSheldon X Kong

❮ Previous
Next ❯

Citations

Aug 10, 2007·Der Nervenarzt·H C DienerV Limmroth
Jan 26, 2008·Der Schmerz·H-C DienerV Limmroth
Aug 28, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·S EversUNKNOWN European Federation of Neurological Societies
Jul 16, 2010·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·G Haag
Jun 30, 2007·Cephalalgia : an International Journal of Headache·Gunther Haag
Jul 31, 2007·Cephalalgia : an International Journal of Headache·E Gretchen Tietjen
Apr 2, 2009·Neuropsychiatric Disease and Treatment·Arnaud Fumal, Jean Schoenen
Jul 1, 2012·Pain Management·Mari Bozoghlanian, Sridhar V Vasudevan
Mar 2, 2010·Expert Review of Neurotherapeutics·José G SpecialiMarcelo E Bigal
Jul 11, 2014·Expert Opinion on Pharmacotherapy·Stephen D Silberstein, Jessica C Stirpe
Jul 22, 2010·Pharmaceuticals·Thierry Favrod-Coune, Barbara Broers
Mar 17, 2015·Expert Opinion on Drug Safety·János TajtiLászló Vécsei
Jul 14, 2010·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Hazel PalmerRichard Day
Feb 4, 2016·Pain Research and Treatment·Rubesh GooriahFayyaz Ahmed
Oct 12, 2010·The Journal of Headache and Pain·Anders Hougaard, Peer Tfelt-Hansen
Apr 20, 2007·Journal of Clinical Pharmacology·Bertold RennerKay Brune
Nov 17, 2010·Fundamental & Clinical Pharmacology·Denis M SoaresGlória E P Souza
Apr 17, 2015·Headache·Werner J Becker
Jun 5, 2012·Revista brasileira de anestesiologia·Cristiane Tavares, Rioko Kimiko Sakata
Mar 3, 2012·Cephalalgia : an International Journal of Headache·Peer Tfelt-HansenUNKNOWN International Headache Society Clinical Trials Subcommittee
Aug 13, 2014·Journal of Pharmacy Practice·Roger CadyRichard Wenzel
Oct 27, 2017·The Journal of Headache and Pain·Richard B LiptonKetu Patel
Aug 16, 2016·Cephalalgia : an International Journal of Headache·Kristian ThorlundPeter J Goadsby
May 2, 2013·The Cochrane Database of Systematic Reviews·Roy RabbieR Andrew Moore
Nov 27, 2010·Current Treatment Options in Neurology·Teshamae S Monteith, Peter J Goadsby
May 6, 2019·Pharmaceutics·Vahideh Vakil, Wade Trappe
Jan 16, 2010·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·K AnnekenI W Husstedt
May 28, 2020·Postgraduate Medicine·Wade CooperVincent Martin
Dec 14, 2016·The Journal of Headache and Pain·Haiyang XuMingxian Li
Mar 30, 2018·Obstetrical & Gynecological Survey·Elisa T BushmanKathleen B Digre
Aug 1, 2020·Nutrients·Magdalena NowaczewskaWojciech Kaźmierczak
Feb 3, 2021·Neurology International·Amber N EdinoffIvan Urits
Nov 18, 2018·Journal of Medicinal Chemistry·Pradipta DasJon T Njardarson
Sep 15, 2021·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·Hans Christoph DienerThomas Weiser

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.